Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

iShares S&P 500 ETF

IVV

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

Barton Gold Holdings Limited

BGD

Barton Gold Holdings Ltd. operates as a gold exploration company. The company is headquartered in Adelaide, South Australia. The company went IPO on 2021-06-28. The firm has a pipeline of advanced exploration projects and brownfield mines, and 100% ownership of the only regional gold mill in the central Gawler Craton of South Australia. The company has about 5,100 square kilometers tenure and joint venture (JV) gold rights in the richly mineralized central Gawler Craton of South Australia. The projects are grouped near the junction of the Perth, Alice Springs / Darwin and Adelaide railways, about 600 kilometers (km) northwest of Adelaide. The company is focused on a series of exploration programs at its Tarcoola, Tunkillia and Challenger projects. The Tarcoola Project is located about 70 km north-northwest of the Tunkillia Project on 1,640 square kilometers of tenements. The Tunkillia Project is located about 70km south-southeast of the Tarcoola Project on a 1,360 square kilometers tenement package. The Challenger Project is located approximately 730 km northwest of Adelaide, South Australia.

BetaShares Nasdaq 100 ETF

NDQ

NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.

Clarity Pharmaceuticals Ltd

CU6

Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. The company is headquartered in Eveleigh, New South Wales. The company went IPO on 2021-08-25. The firm is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. The company is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. The company has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.